Ionis Pharmaceuticals Files 8-K on Operations and Financials

Ticker: IONS · Form: 8-K · Filed: Feb 19, 2025 · CIK: 874015

Sentiment: neutral

Topics: sec-filing, financials, operations

Related Tickers: IONS

TL;DR

IONIS filed an 8-K for financial and operational updates. No major news yet.

AI Summary

On February 19, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text.

Why It Matters

This filing indicates Ionis Pharmaceuticals is providing updates on its financial performance and operational status to the SEC, which is standard for public companies.

Risk Assessment

Risk Level: low — This is a routine filing for an 8-K, indicating standard reporting procedures rather than a specific event or material change.

Key Players & Entities

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided text of the 8-K filing does not detail specific financial results or operational updates; it only indicates that the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.

When was this 8-K report filed with the SEC?

This 8-K report was filed on February 19, 2025.

What is the principal business address of Ionis Pharmaceuticals, Inc.?

The principal executive offices of Ionis Pharmaceuticals, Inc. are located at 2855 Gazelle Court, Carlsbad, CA 92010.

What is the SEC file number for Ionis Pharmaceuticals, Inc.?

The SEC file number for Ionis Pharmaceuticals, Inc. is 000-19125.

What is the SIC code for Ionis Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for Ionis Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding IONIS PHARMACEUTICALS INC (IONS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing